Clinical trials: Glabellar Lines
Glabellar Lines
To Evaluate HU-045 With Moderate to Severe Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT07870694
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Huons Biopharma
Upper Facial Lines, Glabellar Lines
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
The objective of this Phase 2 study is to assess the safety and efficacy of single treatment of trenibotulinumtoxinE and onabotulibumtoxinA combination in adult participants with moderate to severe upper facial lines.
- Trial name
- NCT07871513
- Testing
- TrenibotulinumtoxinE and OnabotulinumtoxinA, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- AbbVie
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to assess the effectiveness and safety of a single dose of Corabotase (also known as IPN10200) compared to placebo (double-blind phase) and how well and safely repeat doses of Corabotase work over…
- Trial name
- LAURITE 2 (NCT07435428)
- Testing
- Corabotase
- Where
- 60 sites in United States, France and 2 more
- Volunteers
- 1,300 people
- Sponsor
- Ipsen
Glabellar Lines
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with botulinum toxin.
- Trial name
- NCT05248893
- Testing
- AGN-151586
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 992 people
- Sponsor
- AbbVie
Moderate to Severe Glabellar Lines
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT06937944
- Testing
- Rcombinant botulinum toxin type A for injection（Eveotox), OnabotulinumtoxinA (Botox)
- Where
- 15 sites in China
- Volunteers
- 669 people
- Sponsor
- JHM BioPharma (Tonghua) Co. , Ltd.
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to find out about the effectiveness and safety of a single dose of corabotase (also known as IPN10200) compared to placebo works in participants with moderate to severe glabellar lines.
- Trial name
- LAURITE 3 (NCT07779252)
- Testing
- Corabotase
- Where
- 9 sites in China
- Volunteers
- 160 people
- Sponsor
- Ipsen
Moderate to Severe Glabellar Lines
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
The purpose of this study is to assess the effectiveness and safety of Corabotase (also known as IPN10200) compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants.
- Trial name
- LAURITE 1 (NCT07427797)
- Testing
- Corabotase
- Where
- 23 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Ipsen
Glabellar Lines
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT07756580
- Testing
- AGN-151586, BOTOX
- Where
- 8 sites in United States
- Volunteers
- 120 people
- Sponsor
- AbbVie
Moderate to Severe Glabellar Lines
A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines
The study is a two-part (Part A and Part B) randomized double-blind vehicle-controlled multi-center study in a total of 174 participants with moderate to severe glabellar lines.
- Trial name
- NCT06481475
- Testing
- YY003, Vehicle Control
- Where
- 3 sites in Australia
- Volunteers
- 153 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Frown Lines
AI-09 In Subjects With Glabellar Lines, GL-101
AI-09 In Subjects with Glabellar Lines
- Trial name
- NCT05565950
- Testing
- AI-09, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eirion Therapeutics Inc.
Glabellar Lines
Study of DWP450 in Japanese Subjects With Glabellar Lines
Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines
- Trial name
- NCT07783763
- Testing
- DWP450 20 U, 0.9% Saline Solution 0.5 mL
- Volunteers
- 120 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Wrinkle, Glabellar Frown Lines
Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides
Study Type: This is a multicenter, triple-blind, randomized controlled trial. Purpose: The goal of this clinical trial is to compare the effectiveness and safety of all commercially available Botulinum Neurotoxin Type A (BoNT-A)…
- Conditions
- Wrinkle, Glabellar Frown Lines, Glabellar Furrowing
- Trial name
- NCT06448676
- Testing
- Botulinum toxin type A
- Where
- 3 sites in Netherlands
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Glabellar Frown Lines
Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
Non-interventional PASS of NUCEIVA for the treatment of moderate-to-severe glabellar lines to provide additional characterisation of the long-term safety of NUCEIVA in the real-world clinical practice setting.
- Trial name
- NCT05481931
- Testing
- prabotulinumtoxinA
- Where
- Germany
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Moderate to Severe Glabellar Lines
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
This is a Multi-center, Open-label Study on the Efficacy and Safety of Multiple Treatments with Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines.
- Trial name
- NCT06583486
- Testing
- Rcombinant botulinum neurotoxin type A for injection (YY001)
- Where
- 16 sites in China
- Volunteers
- 488 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Lines
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT05496335
- Testing
- AGN-151586, BOTOX
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- AbbVie
Moderate to Severe Glabellar Lines
Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT06151561
- Testing
- AGN-151586
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- AbbVie
Glabellar Lines
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT06308198
- Testing
- AGN-151586
- Where
- 12 sites in China, Japan and 1 more
- Volunteers
- 161 people
- Sponsor
- AbbVie
Glabellar Frown Lines
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of CU-20101 in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT06585696
- Testing
- CU-20101 treatment for Moderate to Severe Glabellar Striae, BOTOX®
- Where
- China
- Volunteers
- 554 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Glabellar Lines
Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.
To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.
- Trial name
- NCT07622004
- Testing
- Botulinum Toxin Type A Injection [INI101], Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- INIBIO Co., Ltd.
Glabellar Frown Lines, Canthal Lines
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
This study to assess aesthetic improvement following treatment with QM1114-DP.
- Trial name
- NCT05148000
- Testing
- QM1114-DP
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Galderma R&D